On June 27, 2024, BioNTech SE and Pfizer received a positive recommendation from the European Medicines Agency for their Omicron JN.1-adapted COVID-19 vaccine, aiding in the prevention of COVID-19 for individuals 6 months and older. This is a significant event for the company, reflecting a positive sentiment regarding their vaccine developments.